FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310126577> ?p ?o ?g. }

• W4310126577 endingPage "11837" @default.
• W4310126577 startingPage "11836" @default.
• W4310126577 abstract "Background: Measurable residual disease (MRD) is detected during morphological remission after standard chemotherapy in acute myeloid leukemia (AML) patients (pts). It is a strong prognostic factor for relapse and shorter overall survival (OS). Immunophenotyping by multiparameter flow cytometry (MFC) is currently the most commonly used method in AML pts. There is still a lack of studies evaluating MRD in specific AML populations in the era of targeted therapies, including thyrosine kinase inhibitors. A retrospective study in adult pts with a newly diagnosed AML FLT3+ treated with intensive chemotherapy plus midostaurin has been performed to evaluate the prognostic impact of positive MRD (MRD+) on RFS and OS. Objectives: To assess the prognostic impact of MRD status during the clinical course of AML FLT3+ on RFS and OS. Patients and methods: Seventy three pts with AML FLT3 were treated in Polish hematological centers between 2018 and 2021. Bone marrow aspiration was performed after induction and consolidation treatment to assess response and MRD by MFC. MRD+ was defined as ≥ 0.1% abnormal cells within mononucleated cells by MFC with diagnostic leukemia-associated immunophenotype (LAIP) and different from normal (DfN) aberrant immunophenotype approaches. Results: The median age of the pts was 55 (range: 18-74). Induction regimen was DA 3+7 in 50 (70%), DA-90 in 8 (11%), DAC in 11 (15%), other in 2 (4%) pts. Fifty seven (78%) pts achieved first composite complete remission (CRc=CR+CRi) after 1 or 2 courses of induction, 12 (17%) had primary refractory disease (PRD) and 2 (3%) pts died in aplasia. Median number of consolidation courses was 2 (range: 1-4). Fifty one (89%) pts with CR1 fulfill the criteria for MRD analysis after 1 or 2 courses of induction and 34 (48%) pts after consolidations. Thirty four pts had 2 timepoints evaluation: after induction and at the end of consolidation courses. MRD+ was reported in 35 (68%) of pts after induction (median 0.5; IQR 0.25-0.85) and in 19 (52%) of pts at the end of consolidations (median 0.64; IQR 0.22-1.99). Analysis of 4 pts groups was performed: Group 1.: MRD+ after induction and at the end of consolidations (persistent MRD+)(n=16; 47%); Group 2.: MRD+ after induction with conversion to MRD- at the end of consolidations (n=6; 18%); Group 3.: MRD- after induction with conversion to MRD+ at the end of consolidations (n=2; 6%); Group 4.: MRD- after induction and at the end of consolidations (persistent MRD-)(n=10; 29%); Baseline clinical characteristics were similar between 4 groups regarding age, FLT3-ITD and FLT3-TKD frequency, FLT3-ITD allelic ratio (AR), WBC, PLT, peripheral blood and bone marrow blast percentage, AML type: de novovs sAML vs tAML (p-values > 0.05). The probability of 1- year RFS was significantly lower in pts with persistent MRD+ (group 1.) vs group 2. vs 3. vs 4. (27% vs 83% vs 50% vs 78%; p=0.034, respectively). Relapse rate after 1 year was in group 1. vs 2. vs 3. vs 4.: 73% vs 16% vs 50% vs 20% (p=0.015), respectively. The shorter OS, but insignificant, was noted in group 1. vs 2. vs 3. vs 4. (p=0.49). A univariate analysis revealed that allo-HSCT (hazard ratio [HR] 0.345; 95% confidence interval (CI), 0.152-0.784; p=0.011) and male sex (HR, 0.433; 95% CI, 0.217-0.861; p=0.017) are predictors for longer OS. MRD- at the end of consolidations (HR, 0.211; 95% CI, 0.066-0.669; p=0.008), persistent MRD- (HR, 0.252; 95% CI, 0.070-0.909; p=0.035), allo-HSCT (HR, 0.416; 95% CI, 0.183-0.947; p=0.0368) are predictors for longer RFS. However, older age (HR, 1.049; 95% CI, 1.018-1.081; p=0.0017) and higher WBC (HR, 1.005; 95% CI, 1.002-1.008; p=0.0022) are predictors for shorter RFS. Conclusions: We observed high rate of CR1 MRD+ AML FLT3 pts after induction (68%) and at the end of consolidations (52%). Significantly lower RFS and higher relapse rate, but not OS, were noted in pts with persistent MRD+ in comparison to pts in other MRD groups. Longer follow-up period and larger studies are necessary to confirm our preliminary findings." @default.
• W4310126577 created "2022-11-30" @default.
• W4310126577 creator A5001168227 @default.
• W4310126577 creator A5004764706 @default.
• W4310126577 creator A5005195465 @default.
• W4310126577 creator A5010732325 @default.
• W4310126577 creator A5013522888 @default.
• W4310126577 creator A5017533730 @default.
• W4310126577 creator A5018366313 @default.
• W4310126577 creator A5022628384 @default.
• W4310126577 creator A5025842619 @default.
• W4310126577 creator A5028787736 @default.
• W4310126577 creator A5034883916 @default.
• W4310126577 creator A5036425986 @default.
• W4310126577 creator A5036710633 @default.
• W4310126577 creator A5042552205 @default.
• W4310126577 creator A5053027442 @default.
• W4310126577 creator A5053348808 @default.
• W4310126577 creator A5057058114 @default.
• W4310126577 creator A5058401326 @default.
• W4310126577 creator A5062141453 @default.
• W4310126577 creator A5062641058 @default.
• W4310126577 creator A5063733354 @default.
• W4310126577 creator A5069252766 @default.
• W4310126577 creator A5071060990 @default.
• W4310126577 creator A5076667170 @default.
• W4310126577 creator A5082335171 @default.
• W4310126577 date "2022-11-15" @default.
• W4310126577 modified "2023-10-03" @default.
• W4310126577 title "Prognostic Impact of Persistent Measurable Residual Disease in Patients with Acute Myeloid Leukemia FLT3+ Treated with Intensive Chemotherapy Plus Midostaurin - a Retrospective Study of the Polish Adult Leukemia Group (PALG)" @default.
• W4310126577 doi "https://doi.org/10.1182/blood-2022-170126" @default.
• W4310126577 hasPublicationYear "2022" @default.
• W4310126577 type Work @default.
• W4310126577 citedByCount "0" @default.
• W4310126577 crossrefType "journal-article" @default.
• W4310126577 hasAuthorship W4310126577A5001168227 @default.
• W4310126577 hasAuthorship W4310126577A5004764706 @default.
• W4310126577 hasAuthorship W4310126577A5005195465 @default.
• W4310126577 hasAuthorship W4310126577A5010732325 @default.
• W4310126577 hasAuthorship W4310126577A5013522888 @default.
• W4310126577 hasAuthorship W4310126577A5017533730 @default.
• W4310126577 hasAuthorship W4310126577A5018366313 @default.
• W4310126577 hasAuthorship W4310126577A5022628384 @default.
• W4310126577 hasAuthorship W4310126577A5025842619 @default.
• W4310126577 hasAuthorship W4310126577A5028787736 @default.
• W4310126577 hasAuthorship W4310126577A5034883916 @default.
• W4310126577 hasAuthorship W4310126577A5036425986 @default.
• W4310126577 hasAuthorship W4310126577A5036710633 @default.
• W4310126577 hasAuthorship W4310126577A5042552205 @default.
• W4310126577 hasAuthorship W4310126577A5053027442 @default.
• W4310126577 hasAuthorship W4310126577A5053348808 @default.
• W4310126577 hasAuthorship W4310126577A5057058114 @default.
• W4310126577 hasAuthorship W4310126577A5058401326 @default.
• W4310126577 hasAuthorship W4310126577A5062141453 @default.
• W4310126577 hasAuthorship W4310126577A5062641058 @default.
• W4310126577 hasAuthorship W4310126577A5063733354 @default.
• W4310126577 hasAuthorship W4310126577A5069252766 @default.
• W4310126577 hasAuthorship W4310126577A5071060990 @default.
• W4310126577 hasAuthorship W4310126577A5076667170 @default.
• W4310126577 hasAuthorship W4310126577A5082335171 @default.
• W4310126577 hasConcept C126322002 @default.
• W4310126577 hasConcept C143998085 @default.
• W4310126577 hasConcept C167135981 @default.
• W4310126577 hasConcept C2776481607 @default.
• W4310126577 hasConcept C2776694085 @default.
• W4310126577 hasConcept C2778336483 @default.
• W4310126577 hasConcept C2778461978 @default.
• W4310126577 hasConcept C2778729363 @default.
• W4310126577 hasConcept C71924100 @default.
• W4310126577 hasConceptScore W4310126577C126322002 @default.
• W4310126577 hasConceptScore W4310126577C143998085 @default.
• W4310126577 hasConceptScore W4310126577C167135981 @default.
• W4310126577 hasConceptScore W4310126577C2776481607 @default.
• W4310126577 hasConceptScore W4310126577C2776694085 @default.
• W4310126577 hasConceptScore W4310126577C2778336483 @default.
• W4310126577 hasConceptScore W4310126577C2778461978 @default.
• W4310126577 hasConceptScore W4310126577C2778729363 @default.
• W4310126577 hasConceptScore W4310126577C71924100 @default.
• W4310126577 hasIssue "Supplement 1" @default.
• W4310126577 hasLocation W43101265771 @default.
• W4310126577 hasOpenAccess W4310126577 @default.
• W4310126577 hasPrimaryLocation W43101265771 @default.
• W4310126577 hasRelatedWork W2013419143 @default.
• W4310126577 hasRelatedWork W2028195960 @default.
• W4310126577 hasRelatedWork W2266287318 @default.
• W4310126577 hasRelatedWork W2383491515 @default.
• W4310126577 hasRelatedWork W2406230970 @default.
• W4310126577 hasRelatedWork W2474093006 @default.
• W4310126577 hasRelatedWork W2889180997 @default.
• W4310126577 hasRelatedWork W2952655407 @default.
• W4310126577 hasRelatedWork W4254153790 @default.
• W4310126577 hasRelatedWork W812851151 @default.
• W4310126577 hasVolume "140" @default.
• W4310126577 isParatext "false" @default.
• W4310126577 isRetracted "false" @default.
• W4310126577 workType "article" @default.